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OBJECTIVE—Increased very-low-density lipoprotein triglycer-
ides (VLDL-TG) concentration is a central feature of diabetic
dyslipidemia. The objective was to compare basal and insulin
mediated VLDL-TG kinetics, oxidation, and adipose tissue stor-
age in type 2 diabetic and healthy (nondiabetic) men.
RESEARCH DESIGN AND METHODS—Eleven type 2 dia-
betic and 11 healthy men, matched for BMI and age, were
included. Ex vivo-labeled VLDL-TG tracers, blood and breath
samples, fat biopsies, indirect calorimetry, and body composition
measures were applied to determine VLDL-TG kinetics, VLDL-TG
fatty acids (FA) oxidation, and storage in regional adipose tissue
before and during a hyperinsulinemic euglycaemic clamp.
RESULTS—VLDL-TG secretion was signiﬁcantly greater in dia-
betic compared with healthy men (basal: 86.9 [31.0] vs. 61.9 [30.0]
mol/min, P  0.03; clamp: 60.0 [26.2] vs. 34.2 [17.9] mol 
min
1, P  0.01). The insulin mediated suppression of VLDL-TG
secretion was signiﬁcant in both groups. VLDL-TG clearance was
lower in diabetic men (basal: 84.6 [32.7] vs. 115.4 [44.3] ml 
min
1, P  0.08; clamp: 76.3 [30.6] vs. 119.0 [50.2] ml  min
1, P 
0.03). During hyperinsulinemia fractional VLDL-TG FA oxidation
was comparable, but in percentage of energy expenditure (EE),
signiﬁcantly higher in diabetic men. Basal VLDL-TG storage was
similar, but signiﬁcantly greater in abdominal compared with leg
fat.
CONCLUSIONS—Increased VLDL-TG in type 2 diabetic men
is caused by greater VLDL-TG secretion and less so by lower
VLDL-TG clearance. The ability of hyperinsulinemia to sup-
press VLDL-TG secretion appears preserved. During hyperin-
sulinemia VLDL-TG FA oxidation is signiﬁcantly increased in
proportion of EE in type 2 diabetic men. Greater basal
abdominal VLDL-TG storage may help explain the accumula-
tion of upper-body fat in insulin-resistant individuals.
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T
ype 2 diabetes is associated with dyslipidemia,
which is considered a major risk factor for
coronary heart disease (1–3). It is characterized
by hypertriglyceridemia, low HDL cholesterol
concentrations, small and dense LDL particles, and exces-
sive postprandial lipemia (4–7). Evidence suggests that
increased concentration of very-low-density lipoprotein
triglycerides (VLDL-TG) is a central pathophysiologic fea-
ture of diabetic dyslipidemia (4,5).
Various tracer methods have been applied to study the
mechanisms responsible for hypertriglyceridemia. Most
techniques are based on in vivo labeling; i.e., infusion of
labeled precursors which are eventually incorporated into
either apolipoprotein B100 (apoB-100) or the triglyceride
content of the very-low-density lipoprotein (VLDL) parti-
cles combined with modeling of the subsequent plasma
decay data. Because only one apoB-100 molecule exists
per VLDL particle, VLDL-apoB-100 reﬂects particle num-
ber, whereas VLDL-TG reﬂects the major lipid content of
the particle. Studies have shown that elevated levels of
VLDL-TG in type 2 diabetes is caused by a combination
of increased hepatic secretion of VLDL-apoB-100 (8–10)
and VLDL-TG (10), speciﬁcally in the subfraction of large
triglyceride-rich VLDL (VLDL1) (11,12). This has focused
attention on the impact of insulin on VLDL kinetics. The
acute effect of insulin on VLDL kinetics has been investi-
gated in nondiabetic subjects (13–17). Despite different
modeling approaches the results are quite unambiguous,
showing that acute hyperinsulinemia decreases hepatic
secretion of VLDL-TG (13,14,17) and VLDL-apoB-100 (13–
17), primarily VLDL1-apoB-100 (15–17). However, to our
knowledge, the effect of insulin on VLDL-TG kinetics has
not been studied directly in type 2 diabetic subjects.
These studies were undertaken to compare basal and
insulin-mediated VLDL-TG kinetics in type 2 diabetic and
healthy men. A secondary objective was to assess periph-
eral VLDL-TG fatty acids (FA) metabolism, i.e., to what
extent VLDL-TG FA are oxidized and stored in regional
adipose tissue. This is relevant in the context of VLDL-TG
as a potentially important energy source and its contribu-
tion to fat accumulation in speciﬁc adipose tissue depots.
RESEARCH DESIGN AND METHODS
This study was approved by the local Ethics Committee and informed consent
was obtained from all participants.
Eleven type 2 diabetic men and 11 healthy men with no family history of
type 2 diabetes, matched for BMI and age, were recruited from the outpatient
clinic and through local advertisements. All were nonsmokers, weight stable,
and not regularly engaged in vigorous exercise. Current diabetes treatments
were lifestyle modiﬁcations alone in six patients and either metformin,
sulfonylurea, or both in ﬁve patients. Oral hypoglycemic agents were discon-
tinued 3 weeks before the study day, and statins and antihypertensive drugs 2
weeks before. All had normal blood count and normal liver and kidney
function (Table 1).
Protocol. Screening of potentially eligible subjects was performed after an
overnight 12-h fast. A medical history was obtained, and blood samples drawn
for lipid proﬁle, A1C, liver and kidney function, and complete blood count.
One week before the study day, subjects meeting the eligibility criteria
visited the Clinical Research Center after an overnight fast. Blood was drawn
for ex vivo labeling of VLDL-TG as described below. Dual x-ray absorptiom-
etry (DXA) scan and abdominal CT scan at the L2-L3 interspace were
performed to obtain anthropometric indexes. Volunteers were interviewed by
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consumed a weight-maintaining diet (55% carbohydrate, 15% protein, and 30%
fat) provided by the hospital kitchen during the 3 days preceding the
metabolic study.
Volunteers were admitted to the Research Center at 22:00 h the evening
before the study. From this time and until the end of the study, they fasted and
remained in bed. At 05.30 h (t  120 min) an intravenous catheter was
placed in an antecubital vein and a bolus of [9,10-
3H]VLDL-TG was infused.
Another catheter was placed in a dorsal hand vein for blood sampling. The
hand was placed in a heated box to obtain arterialized blood. At 07.30 (t  0),
20% of the [1-
14C]VLDL-TG tracer was infused as a bolus and a constant
infusion with the remaining 80% was started. At t  120 min, a 5-h infusion (1.0
mU  kg FFM
1  min
1) of human insulin (Actrapid; Novo Nordisk A/S)
commenced (FFM represents fat-free mass). Plasma glucose was measured
every 10 min and clamped at 5 mmol  l
1 by a variable infusion of 20% glucose.
The glucose infusion rate during the last hour of the clamp (M value) was used
as an index of insulin sensitivity. Blood samples were drawn to determine
VLDL-TG speciﬁc activity (SA) at t  0, 60, 80, 100, and 120 min (basal period)
and 180, 240, 300, 360, 380, 400, and 420 min (clamp period). Insulin and
metabolite concentrations were determined every 60 min and ApoB-100
concentration at the end of each period. Breath samples to determine
14CO2
SA were obtained at 0, 80, 100, 120, 380, 400, and 420 min. Indirect calorimetry
was performed from t  60 to 80 min and from 360 to 380 min. At t  120 min,
fat biopsies were obtained from the abdominal (periumbilical) and femoral
(inner thigh) regions using a liposuction technique. At 420 min, all catheters
were removed and the participants discharged. The protocol is illustrated in
Fig. 1.
VLDL-TG tracer preparation. The ex vivo labeling procedure of VLDL-TG
with radio labeled triolein has previously been described in detail (18,19).
Brieﬂy, each half of the plasma obtained from a 120-ml blood sample was
mixed with either [1-
14C]triolein or [9,10-
3H]triolein and sonicated in a cell
incubator at 37°C for 6 h. The plasma was transferred to sterile Optiseal
centrifuge tubes (Beckman Instruments), covered with a saline solution (d 
1.006 g  ml
1), and centrifuged (Ti 50.3 rotor; Beckman Instruments) for 18 h
at 40,000 rpm and 10°C. The supernatant containing the labeled VLDL particles
was removed using a sterile Pasteur pipette, ﬁltered, and stored at 5°C.
Samples were tested for bacterial growth to ensure sterility.
Body composition. Total body fat, leg fat, fat percentage, and fat-free mass
(FFM) were examined by dual X-ray absorptiometry (DXA) scanning (QDR-
2000; Hologic). Upper-body fat and visceral fat mass were assessed using the
CT measures of intra-abdominal and subcutaneous adipose tissue combined
with abdominal fat mass measured by DXA as previously described (20).
Abdominal subcutaneous fat was taken as upper body fat minus visceral fat.
Leg fat was measured using the region of interest program with the DXA
instrument.
Indirect calorimetry. Energy expenditure (EE) and substrate oxidation
rates were measured by indirect calorimetry (Deltatrac monitor; Datex
Instruments) and net lipid and glucose oxidation rates were calculated by
using the nonprotein respiratory quotient from the above measurements (21).
Laboratory procedures. Plasma glucose was analyzed using a YSI 2,300
STAT Plus glucose analyzer (YSI). Blood samples were placed on ice and
separated as quickly as possible by centrifugation (3,600 rpm at 4°C for 10
min). Aliquots of plasma (3 ml) were stored at 4°C for isolation of VLDL
immediately after completion of the examination as described below. Remain-
ing samples were stored at 20°C for later analysis. Triglyceride concentra-
tions were analyzed using a Cobas Fara II (F. Hoffmann-La Roche). Serum
insulin concentrations were measured with an immunoassay (DAKO Denmark
A/S). Serum free fatty acid (FFA) concentrations were determined by a
colorimetric method using a commercial kit (Wako Pure Chemical Industries).
ApoB-100 concentration in the supernatant following ultracentrifugation (see
below) was determined using an ELISA kit (Mabtech). Duplicate samples
were diluted to ensure reading on the linear part of the standard curve.
TABLE 1
Subject characteristics
Healthy men
(n  11)
Type 2 diabetic
men (n  11)
Age (years) 49  10 53  12
Weight (kg) 98.8  9.1 93.3  10.7
BMI (kg/m
2) 29.1 (24.4–31.4) 30.6 (25.8–35.6)
FFM (kg) 68.7  4.9 63.2  5.6*
Fat mass (kg) 25.2  6.9 26.0  6.2
Visceral fat (kg) 3.6  1.1 4.3  1.1
Abdominal sc fat (kg) 11.2  3.7 12.6  3.4
Leg fat (kg) 9.3  2.8 8.1  2.2
Fat % 25.7  5.4 28.0  4.1
HbA1c (%) 5.4  0.4 6.8  0.8‡
Triglycerides (mmol/l) 1.10 (0.80–1.88) 1.68 (1.17–3.77)†
Total cholesterol (mmol/l) 4.6  0.7 4.9  0.6
LDL cholesterol (mmol/l) 3.0  0.6 3.0  0.5
HDL cholesterol (mmol/l) 1.1 (0.8–1.5) 0.9 (0.7–1.3)
Data are mean  SD or median (range). FFM, fat-free mass; sc,
subcutaneous. *P  0.05, †P  0.01, ‡P  0.001 vs. healthy men.
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FIG. 1. Study protocol.
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3H-TG SA. Adipose tissue lipid SA (dpm  g
1) was measured
after lipid extraction from adipose tissue biopsies as previously described
(22). In brief, extracted lipid was weighed, scintillation cocktail (Optiphase
HiSafe 2; PerkinElmer) was added, mixed thoroughly, and
3H activity was
counted.
Breath
14CO2 SA. Breath samples were obtained using breath bags (IRIS
breath bags, Wagner Analysen Technik). Expired air was passed through a
solution containing benzethonium hydroxide (Sigma-Aldrich) with thymol-
phthalein (Sigma-Aldrich) in a scintillation vial. A color change occurred when
exactly 0.25 mmol CO2 was trapped in the solution. Scintillation ﬂuid was
added and
14C activity was counted. Total CO2 production rate was obtained
from the indirect calorimetry measurements.
Plasma VLDL-TG concentration and SA. VLDL was isolated from 3m lo f
each plasma sample by ultracentrifugation as described above. The superna-
tant containing the VLDL fraction was obtained by tubeslicing (Beckman
Instruments) and transferred to a scintillation vial. A small sample was
analyzed for triglyceride concentration, and the plasma concentration of
VLDL-TG was calculated. Scintillation ﬂuid was added, and
14C activity was
counted.
Calculations
VLDL-TG secretion rate. VLDL-TG SA steady state was effectively reached
during the last hour of each of the basal and the clamp period. VLDL-TG
secretion rate (mol  min
1) was calculated by dividing the infusion rate by
the plateau SA in each period:
VLDL-TG secretion rate 
F
SA
VLDL-TG clearance. VLDL-TG clearance rate (ml  min
1) was calculated by
dividing the secretion rate by the average VLDL-TG concentration in each
period:
VLDL-TG clearance rate 
VLDL-TG secretion rate
CVLDL-TG
VLDL-TG FA oxidation. Fractional oxidation (percentage) of the infused
[1-
14C]VLDL-TG was calculated as follows:
Fractional VLDL-TG oxidation 
14CO2 SA  VCO2
k  Ar  F
Here, k is the volume of CO2 at 20°C and 1 atm pressure (22.4 l  mol
1) and
Ar is the fractional acetate carbon recovery factor in breath CO2,a n dFi st h e
tracer infusion rate. Sidossis et al. (23) calculated Ar to be 0.56 for resting
conditions and 0.5 for hyperinsulinemia, respectively. The total VLDL-TG FA
oxidation rate (mol  min
1) was calculated as follows and multiplied by
three to allow for three FAs in each triglyceride:
VLDL-TG oxidation rate  Fractional VLDL-TG oxidation
 VLDL-TG secretion rate
To calculate energy production (kcal  day
1) from VLDL-TG FA oxidation,
the oxidation rate was converted to its weight equivalent using the molecular
weight of oleic acid (282 g  mol
1) and multiplied by the caloric density of 9.1
kcal  g
1 and 1,440 min  day
1.
Adipose tissue VLDL-TG FA storage. Fractional adipose tissue VLDL-TG
FA storage (percentage) in abdominal and leg fat was calculated using the
regional (abdomen or thigh) adipose lipid SA multiplied by the total amount of
lipid in the region divided by the injected dose. The VLDL-TG storage rates
(mol  min
1) in speciﬁc regions were calculated as the fractional storage
multiplied by VLDL-TG secretion rate.
Statistics. Data are mean (SD) or median (range). Between groups, compar-
isons were performed using the Student t test or Mann-Whitney test. Within
groups, comparisons were performed using Student t test for paired compar-
isons or Wilcoxon test. Adipose tissue storage values were log transformed to
obtain normal distribution before statistical processing. Correlations were
tested using the Pearson r or Spearman . P  0.05 was considered signiﬁcant.
RESULTS
Subject characteristics. Subject characteristics are sum-
marized in Table 1. The groups were well matched for age
and BMI, and there was no signiﬁcant difference in body
composition indexes except FFM. As expected, greater
A1C (6.8 [0.8] vs. 5.4 [0.4]% P  0.001) and triglycerides
(1.68 [1.17–3.77 ] vs. 1.10 [0.80–1.88 ] mmol  l
1, P  0.01)
was noted in type 2 diabetic men.
Circulating metabolites and insulin. Concentrations of
glucose, triglycerides, VLDL-TG, FFA, and insulin are
shown in Fig. 2. In the basal period, glucose, VLDL-TG, and
insulin were signiﬁcantly greater in diabetic men com-
pared with healthy men, whereas there was no signiﬁcant
difference in FFA concentrations. During the clamp,
plasma glucose gradually decreased in diabetic men to the
target of 5 mmol  l
1. Although hyperinsulinemia re-
sulted in near complete suppression of FFA (P  0.001,
both groups), the decrease in plasma VLDL-TG was more
modest, but still highly signiﬁcant (P  0.001 in both
groups). In absolute numbers the decrease in VLDL-TG
was comparable (0.24 [0.15] vs. 0.25 [0.11] mmol  l
1,
ns); however, the relative decrease was signiﬁcantly
greater in healthy subjects (23.9 [18.2] vs. 44.1 [15.7]%
P  0.01). The resulting VLDL-TG concentration was
signiﬁcantly greater in diabetic men compared with
healthy men, whereas there was no signiﬁcant difference
in glucose, insulin, or FFA concentrations between the
groups during the clamp.
Metabolic parameters. Metabolic parameters are sum-
marized in Table 2. In the basal state, glucose oxidation
rates were similar, but lipid oxidation rates were signiﬁ-
cantly lower in diabetic men compared with healthy men
(0.57 [0.19] vs. 0.74 [0.14] mg  kg
1  min
1, P  0.02).
Conversely, there were no signiﬁcant differences in glu-
cose and lipid oxidation rates or respiratory quotient (RQ)
during hyperinsulinemia. As expected, insulin-mediated
glucose disposal rate was signiﬁcantly reduced in diabetic
men (5.1 [3.3] vs. 9.0 [3.7] mg  kg
1  min
1, P  0.02).
VLDL-TG secretion and clearance. VLDL-TG SA steady
state was effectively reached in the last hour of both the
basal and the clamp period (Fig. 3A). VLDL-TG secretion
(Fig. 3B) was signiﬁcantly greater in diabetic men com-
pared with healthy men in both the basal state (86.9 [31.0]
vs. 61.9 [30.0] mol  min
1, P  0.03) and during hyper-
insulinemia (60.0 [26.2] vs. 34.2 [17.9] mol  min
1, P 
0.01). The suppression of VLDL-TG secretion was highly
signiﬁcant in both groups (P  0.001, both groups).
Moreover, the suppression was comparable between
groups both in absolute numbers (26.9 [17.2] vs. 27.7
[16.9] mol  min
1, ns) and in percentage (30.6 [20.7] vs.
43.6 [15.4]%, ns). VLDL-TG clearance (Fig. 3C) was lower
in diabetic men compared with healthy men in both
periods, although signiﬁcant only during the clamp (84.6
[32.7] vs. 115.4 [44.3] ml  min
1, P  0.08) and (76.3 [30.6]
vs. 119.0 [50.2] ml  min
1, P  0.03), respectively. There
was no signiﬁcant change in VLDL-TG clearance in either
group or in the change between the groups.
VLDL-apoB-100 concentration and VLDL-TG/VLDL-
apoB-100 ratio. Plasma VLDL-apoB-100 concentration
was signiﬁcantly greater in diabetic men compared with
healthy men in both the basal state (16.3 [10.1–42.2 ] vs.
12.2 [4.6–17.1 ] mg  dl
1, P  0.02) and during hyperinsu-
linemia (12.8 [9.7–40.0 ] vs. 7.7 [3.5–17.6 ] mg  dl
1, P 
0.01). A slight, nonsigniﬁcant decrease was noted in both
groups during hyperinsulinemia. The decrease was not
signiﬁcantly different between the groups. The VLDL-TG/
VLDL-apoB-100 ratio was comparable in the two groups in
the basal state (6.1 [2.0] vs. 5.6 [1.3]  10
3 mmol  mg
1,
ns) but signiﬁcantly higher in diabetic men during hyper-
insulinemia (4.8 [1.1] vs. 3.6 [0.9]  10
3 mmol  mg
1, P 
0.02) (Fig. 3E). The decrease in the ratio during the clamp
was signiﬁcant in both groups but less so in diabetic men,
although only the relative decrease was signiﬁcantly dif-
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P  0.03).
VLDL-TG FA oxidation. Breath
14CO2 SA steady state
was reached in the clamp period, but not in the basal
period, allowing calculation of VLDL-TG FA oxidation only
during the clamp. VLDL-TG FA oxidation during the clamp
is depicted in Fig. 4B–D. The fraction of VLDL-TG secre-
tion that was oxidized was comparable in diabetic and
healthy men (44.8 [12.1] vs. 49.6 [10.4]%, ns). However,
total VLDL-TG FA oxidation tended to be greater in
diabetic compared with healthy men (27.7 [14.2] vs. 17.6
[12.2] mol  min
1, P  0.09). Expressed as a fraction of
EE, the contribution from VLDL-TG FA to total substrate
oxidation was signiﬁcantly greater in diabetic men (16.7
[7.9] vs. 9.6 [6.3]%, P  0.03).
VLDL-TG FA adipose tissue storage. At 120 min (4 h
after bolus infusion of [9,10-
3H]VLDL-TG), the remaining
3H plasma activity was (6.1 [2.2–20.1]% vs. 5.8 [2.3–8.0], ns,
diabetic vs. healthy men, respectively). This was calcu-
lated by dividing plasma
3H activity (dpm  ml
1)a t1 2 0
min by the initial activity estimated by dividing infused
activity (dpm) by plasma volume (55 ml  kg FFM
1) (24).
Fractional VLDL-TG FA storage was comparable in the
groups both in abdominal (4.2 [2.9] vs. 4.2 [2.3]%, ns) and
leg fat (1.0 [0.3–4.8 ] vs. 0.8 [0.2–5.5]%, ns) but signiﬁcantly
greater in abdominal compared with leg fat (Fig. 5). Since
practically all
3H activity had disappeared from plasma at
120 min, it is possible to estimate the rate of VLDL-TG FA
storage in the tissues by multiplying fractional storage by
turnover rate. Despite the difference in VLDL-TG secretion
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and healthy men in VLDL-TG FA storage rate in abdominal
(2.7 [1.3–7.0 ] vs. 2.0 [0.5–5.6 ] mol  min
1, ns) or in leg
fat (1.0 [0.2–3.4 ] vs. 0.4 [0.1–4.7 ] mol  min
1, ns).
However, storage rate was signiﬁcantly greater in abdom-
inal fat compared with leg fat in both groups (Fig. 5).
Correlations. No signiﬁcant within-group correlations
were found between VLDL-TG secretion rates and M-value
or concentrations of glucose, FFA, or insulin in the basal
period or between the relative decrease in VLDL-TG
secretion and clearance rates and M-value in the clamp
period.
DISCUSSION
These studies were undertaken to perform comprehensive
comparisons of VLDL-TG kinetics and metabolism in type
2 diabetic men and healthy, age- and BMI-matched men.
We report several novel ﬁndings. First, VLDL-TG secretion
is signiﬁcantly increased in type 2 diabetic men, both
postabsorptively and during hyperinsulinemia, and in ad-
dition, the ability of hyperinsulinemia to suppress
VLDL-TG secretion in type 2 diabetic men appears pre-
served. Second, fractional VLDL-TG FA oxidation is simi-
lar and quantitatively important during hyperinsulinemia
in both type 2 diabetic and healthy men. Third, storage
pattern of VLDL-TG FA is similar in both groups, with
signiﬁcantly greater storage in abdominal subcutaneous
fat compared with leg fat.
Our ﬁndings support and extend results from previous
reports showing that increased postabsorptive VLDL-TG
concentrations in type 2 diabetes results from hepatic
hypersecretion (8–12) and adds new information regard-
ing the effect of insulin on VLDL kinetics (13–17). In
addition to increased VLDL-TG secretion, we found that
VLDL-TG clearance is lower in diabetic men compared
with healthy men, although the difference was signiﬁcant
only during hyperinsulinemia. Therefore, we conclude that
the increased plasma VLDL-TG concentrations observed in
type 2 diabetic men is primarily explained by increased
VLDL-TG secretion and only to a lesser degree by de-
creased VLDL-TG clearance.
To our knowledge, the effect of experimental hyperin-
sulinemia on VLDL-TG kinetics in type 2 diabetic patients
and healthy subjects has not previously been compared
directly. In one study, the effect of insulin on VLDL
kinetics was compared in subjects with high liver fat (80%
with type 2 diabetes) and low liver fat (all nondiabetic)
(17). Hyperinsulinemia resulted in a rapid decline in
VLDL1-TG and -apoB-100 secretion in the group with low
liver fat, whereas there was no signiﬁcant change in VLDL1
secretion in the group with high liver fat. However, the
study was designed to study the effect of liver fat content
rather than type 2 diabetes on VLDL kinetics. The effect of
hyperinsulinemia on VLDL-apoB-100 kinetics in type 2
diabetes has been studied in a few studies, but results are
conﬂicting (25,26). However, lack of a healthy control
group in the ﬁrst study may explain the difference. In the
present study VLDL-apoB-100 concentration was signiﬁ-
cantly greater in type 2 diabetic men compared with
healthy men, and there was no change in concentrations
during hyperinsulinemia. In addition, the VLDL-TG/VLDL-
apoB-100 ratio, a measure of VLDL particle size, was
comparable in the basal state, but decreased signiﬁcantly
in both groups during hyperinsulinemia. This indicates
that postabsorptively, type 2 diabetic men secrete more—
not larger—VLDL particles than healthy men and that
hyperinsulinemia decreases the average particle triglycer-
ide content without changing the particle number. This
effect was, however, attenuated in type 2 diabetic men
since the relative decrease in VLDL-TG/VLDL-apoB-100
ratio was signiﬁcantly greater in healthy men.
As a novel observation we found that VLDL-TG FA
oxidation during hyperinsulinemia accounted for 50% of
VLDL-TG turnover, equivalent to 16.7% and 9.6% of total
EE, which was signiﬁcantly greater in type 2 diabetic men
compared with healthy men. In the basal state, the poten-
tial VLDL-TG energy yield, that is, if all circulating
VLDL-TG is oxidized, was 40% of EE. Since we did not
achieve steady state in breath
14CO2 in the basal period,
we cannot estimate basal VLDL-TG FA oxidation. How-
ever, we recently reported basal VLDL-TG FA oxidation
rates of 20% of EE in obese, insulin-resistant, and lean
women (27). In the present study, the fractional oxidation
of VLDL-TG FA during hyperinsulinemia was comparable
in the two groups. However, because of the greater
VLDL-TG secretion rate, VLDL-TG oxidation rates tended
to be greater in type 2 diabetic men. The greater VLDL-TG
oxidation in relation to EE in type 2 diabetic men com-
pared with healthy men suggests a decreased capacity of
insulin to suppress VLDL-TG oxidation in type 2 diabetic
men. This is interesting in the context of “metabolic
inﬂexibility” in type 2 diabetes, i.e., reduced capacity to
shift appropriately between lipid and carbohydrate fuels
for oxidation (28). Thus, we propose to extend the concept
TABLE 2
Circulating metabolites, insulin, and metabolic parameters in the basal state and during hyperinsulinemia
Healthy men (n  11) Type 2 diabetic men (n  11)
Basal Clamp Basal Clamp
Glucose (mmol/l) 5.5 (4.5–6.7) 4.9 (4.6–5.3) 6.8 (5.8–14.7)‡ 5.0 (4.9–6.7)
FFA (mmol/l) 0.43  0.12 0.03 (0.02–0.16) 0.42  0.13 0.05 (0.01–0.23)
VLDL-TG (mmol/l) 0.54 (0.31–1.10) 0.28 (0.13–0.63) 0.92 (0.64–2.70)† 0.70 (0.25–2.15)†
Insulin (pmol/l) 27 (18–66) 320  31 65 (22–118)† 345  46
EE (kcal/day) 1,956  125 2,021  131 1,876  197 1,819  190†§
RQ 0.81  0.04 0.89  0.05 0.85  0.04* 0.88  0.05
Glucose oxidation (mg/kg/min) 1.02  0.52 2.09  0.72 1.42  0.55 1.80  0.68§
Lipid oxidation (mg/kg/min) 0.74  0.14 0.37  0.23 0.57  0.19* 0.38  0.23
GIR (mg/kg/min) 9.0  3.7 5.1  3.3*
Data are mean  SD or median (range). EE, energy expenditure; FFA, free fatty acids; GIR, glucose infusion rate; RQ, respiratory quotient;
VLDL-TG, very low density lipoprotein triglyceride. *P  0.05; †P  0.01; ‡P  0.001 vs. healthy men. §P  0.05; P  0.01 difference
(basal-clamp) vs. difference (basal-clamp) in healthy men.
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failure to suppress VLDL-TG FA oxidation during
hyperinsulinemia.
Finally, we report that the fractions of circulating
VLDL-TG FA that are stored in abdominal and leg fat are
similar in type 2 diabetic and healthy men who have a
similar amount of fat tissue. However, the VLDL-TG FA
storage rate is somewhat greater, although not signiﬁ-
cantly, in type 2 diabetic men compared with healthy men
in both abdominal and leg fat (Fig. 5). Both the fractional
storage and the storage rate were signiﬁcantly greater in
abdominal fat compared with leg fat in both groups. This
difference cannot be ascribed to a greater amount of
abdominal fat compared with leg fat. Thus, abdominal
subcutaneous fat mass was only 25% greater than leg fat
mass, whereas storage was 3 times greater in abdominal
fat. Therefore, storage per kg fat was signiﬁcantly greater
in abdominal fat compared with leg fat in both groups. In
a recent study of obese and lean women, we reported
similar VLDL-TG factional storage and storage rates in
abdominal and leg fat in upper-body obese women. Both
fractional storage and storage rates in abdominal fat were
similar to the values found in men in the present study.
However, leg fat storage was much less in men in the
present study compared with the obese women of the
previous study (27). We believe that the present study is
the ﬁrst to report postabsorptive VLDL-TG storage rates in
regional fat in type 2 diabetic men in comparison with
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information to explain the preferential fat accumulation in
abdominal fat in upper-body obese subjects.
We acknowledge the limitations of our study. The
inability to detect a signiﬁcant difference between groups
in suppression of VLDL-TG secretion may represent a type
2 error. At least our data indicate that insulin affects
VLDL-TG kinetics differently in the two groups. Basal
VLDL-TG secretion rates are signiﬁcantly greater in type 2
diabetic men despite signiﬁcantly higher insulin concen-
trations. Moreover, the relative decrease in VLDL-TG
concentration and VLDL-TG/VLDL-apoB-100 ratio was sig-
niﬁcantly lower in type 2 diabetic men. In addition, the
capacity of insulin to reduce VLDL-TG secretion could be
proportionally less pronounced at lower (physiologic)
insulin levels in type 2 diabetic than in healthy men. In
comparison, suppression of glucose production is im-
paired in type 2 diabetic subjects compared with weight-
matched healthy subjects at physiologic, but not
supraphysiologic, insulin concentrations (29). VLDL-TG
oxidation rates were calculated by multiplying fractional
oxidation by VLDL-TG turnover. Obviously, if either pa-
rameter is overestimated, the oxidation rates are overes-
timated. The optimal approach would be measurement of
acetate recovery in each experiment, since the recovery
dependents on, e.g., EE and tracer infusion duration. The
VLDL-TG secretion rates reported in our study are higher
than values reported in most studies based on precursor
labeling and compartmental modeling (30,31). However,
traditional tracer dilution technique and noncompartmen-
tal modeling is a conceptually more simple approach that
allows calculation of kinetic parameters of interest with-
out the assumptions inherent to methods based on com-
partmental modeling. Importantly, the VLDL-TG secretion
rates reported in the present study are in reasonable
agreement with values from studies using other model-
independent methods, e.g., splanchnic differences and
studies using primed-constant reinfusion of endogenously
labeled VLDL-TG tracer as discussed in detail previously
(19). We also acknowledge the use of a VLDL-TG tracer
prepared from VLDL-TG particles during fasting, which
may not be representative to the VLDL-TG particle com-
position during hyperinsulinemia. Ideally, VLDL-TG sam-
pling for tracer preparation should be performed during
hyperinsulinemia. Using this approach, Lewis et al.(13)
reported unaltered VLDL-ApoB-100 kinetics. Moreover, we
found no published information regarding the impact of
altered plasma particle composition on the peripheral fate
of VLDL-TG FA. Finally, we cannot extend our ﬁndings to
type 2 diabetic women.
In conclusion, this study demonstrates that the in-
creased VLDL-TG concentration in type 2 diabetic men
results from increased hepatic VLDL-TG secretion, and
that the ability of hyperinsulinemia to suppress
VLDL-TG secretion is preserved in type 2 diabetic men
at this relatively high insulin dose. Moreover, VLDL-TG
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and constitutes a signiﬁcantly greater proportion of EE
in type 2 diabetic men (17%) compared with age- and
weight-matched men (10%). Finally, both type 2 diabetic
and healthy men store more VLDL-TG in abdominal fat
than in leg fat, which may provide a mechanism
whereby some individuals develop a preferential upper-
body fat distribution.
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